Serum IFN-γ levels predict the therapeutic effect of mesenchymal stem cell transplantation in active rheumatoid arthritis

Yi Yang1,2†, Xiao He1†, Rongseng Zhao1, Wei Guo1, Ming Zhu1, Wei Xing1, Dongpo Jiang3, Chongyang Liu2* and Xiang Xu1*†

Abstract

Background: To explore the mechanism of the different clinical efficacies of mesenchymal stem cell transplantation (MSCT) and identify a possible serum biomarker for predicting the therapeutic effect of MSCT in rheumatoid arthritis (RA) patients.

Methods: A total of 105 patients with persistently active RA and poor responses to traditional medication were randomly divided into MSCT and control groups. Outcomes were evaluated according to the 28-joint Disease Activity Score and Health Assessment Questionnaire, serological indicators, regulatory T cell (Treg) to T helper 17 (Th17) cell ratio, and inflammatory cytokine levels. Twelve weeks after MSCT, the outcomes of the MSCT group were evaluated according to the European League against Rheumatism response criteria. Patients with a good or moderate response were added to the response group, and those with no response were added to the no-response group.

Results: No serious adverse events were reported for either MSCT subgroup (28 in the response group and 24 in the no-response group). The therapeutic effects lasted for 48 weeks without continuous administration. Notably, a transient increase in serum IFN-γ (>2 pg/ml) levels was observed in the response group, but not in the no-response group. Furthermore, an increase in IL-10 levels and the Treg/Th17 ratio and a reduction in IL-6 levels appeared 2–3 weeks after the transient IFN-γ increase.

Conclusions: Allogeneic MSCT is safe and feasible, and we propose high serum IFN-γ levels as a potent biomarker for predicting MSCT response.

Trial registration chict.org, ChiCTR-ONC-16008770. Registered 3 July 2016, [http://www.chict.org.cn/showproj.aspx?proj=14820](http://www.chict.org.cn/showproj.aspx?proj=14820)

Keywords: Mesenchymal stem cell, Rheumatoid arthritis, IFN-γ, Clinical trial

© The Author(s) 2018, corrected publication 2021. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Rheumatoid arthritis (RA) is chronic synovitis characterized by articular inflammation, synovial joint damage and deteriorating disability over time. The basic pathogenic mechanisms that initiate and promote RA progression are likely to be systemic and synovial inflammation due to unbalanced immune homeostasis, possibly involving genetic and environmental factors.

In the BeSt study, 508 RA patients were treated with hormones, disease-modifying antirheumatic drugs (DMARDs), or biological agents and were followed for up to 5 years; according to the results, more than 50% of the RA patients did not achieve clinical remission after treatment [1]. Therefore, despite great medical advances, the following problems remain: (i) some patients cannot tolerate DMARDs or biologics; and (ii) biologic agents are expensive and weaken the immune system, thus potentially increasing the risk of infections. Consequently, novel treatment options for RA patients are urgently needed.

Mesenchymal stem cells (MSCs) are multipotent cells derived from bone marrow or other connective tissues, such as the umbilical cord; MSCs have the capacity to self-renew and differentiate into mesenchymal tissues [2]. In addition to their differentiation ability, MSCs have immunomodulatory effects on many diseases [3, 4]. MSCs can inhibit the proliferation of activated peripheral blood mononuclear cells (PBMCs) and T lymphocytes [5] to induce regulatory T cell (Treg) differentiation and inhibit T helper 17 (Th17) cell function [6]; it is through these mechanisms that MSCs exert their immunomodulatory effects on RA. The immunomodulatory abilities of MSCs are thought to depend on interferon-γ (IFN-γ)-induced indoleamine 2,3-dioxygenase (IDO). The unique immunomodulatory properties of MSCs make them a promising candidate cell therapy for tissue repair, potentially for use in treating immune disorders, such as graft-versus-host disease (GVHD) [7], and autoimmune diseases, such as systemic lupus erythematosus (SLE) [8]; however, contradictory results have been reported for using MSC transplantation (MSCT) to treat RA [9, 10]. There are huge individual variations in the clinical efficacy of MSCT for the same disease, but the reasons for this are unclear. For the widespread clinical application of MSCT, a better understanding of the biological properties of MSCs is required. This information would help clarify the mechanisms of MSC-based transplantation for immunomodulation and improve clinical efficacy.

In this study, we aimed to determine the different clinical efficacy of MSCT in RA patients and to identify a possible serum biomarker for predicting the therapeutic effects of MSCT.

Methods
Patient eligibility
All patients met the American College of Rheumatology 1987 (ACR1987) criteria for RA classification and had no other autoimmune or systemic diseases. Written informed consent was provided in accordance with the Declaration of Helsinki. The study was registered at Chictr.org (identifier: ChiCTR-ONC-16008770) and approved by the Ethics Committee of Daping Hospital, Third Military Medical University of the Chinese People’s Liberation Army (YIYANLUNSHEN (2016) NO. 007). The enrolled RA patients responded poorly to regular clinical strategies, including DMARDs, non-steroidal anti-inflammatory drugs (NSAIDs), steroids and biologics, or could not tolerate their serious side effects; thus, the patients maintained active disease conditions (Additional file 1: Table S1). Overall, 105 RA patients were enrolled from July 2016 to March 2017.

Treatment protocol
Patients were randomly divided into MSCT and control groups. Source and preparation of umbilical cord-derived human MSCs (UCMSCs) were detailed in Additional file 2. The patients received either 1 × 10^6 cells/kg body weight in 50 mL of 1% albumin in physiological saline as the treatment or 50 mL of 1% albumin in physiological saline without UCMSCs as the control via intravenous infusion. If the status of the patient continued to improve, a withdrawal schedule was used to taper off conventional drug treatment in the following order: prednisone acetate, then NSAIDs and DMARDs. All treatment modifications were agreed upon by the rheumatologist in charge.

Assessment of disease status
All patients returned for scheduled follow-up visits at 1, 2, 3, 4, 12, 24, and 48 weeks. At these time points, the adverse events, general physical status, serological indicators, and Treg to Th17 cell ratio of the patients were examined and recorded. The 28-joint Disease Activity Score (DAS28) and Health Assessment Questionnaire (HAQ) were assessed at baseline and each follow-up visit for each patient. Specifically, to determine the different clinical efficacies of MSCT in RA patients, outcomes for the MSCT group were evaluated according to the European League against Rheumatism (EULAR) response criteria, which consider both the current DAS28 value and any reduction after treatment. Patients with a good or moderate response were added to the response group, and those with no response were added to the no-response group at 12 weeks after MSCT (Fig. 1).
Laboratory tests
Serum levels of anti-cyclic citrullinated peptide antibody (anti-CCP) and rheumatoid factor (RF) were determined by indirect immunofluorescence using kits purchased from Euroimmun (Lübeck, Germany). The percentages of peripheral blood Tregs and Th17 cells were analyzed by flow cytometry (NovoCyte™, ACEA Biosciences, San Diego, CA USA). Monoclonal antibodies against CD4, CD25, Foxp3 and IL-17A were purchased from BD. Flow cytometry data were analyzed with NovoExpress software (ACEA Biosciences, San Diego, CA USA). A bead-based multiplex cytokine assay was custom-designed to quantify the following cytokines: TNF-α, IFN-γ, IL-1β, IL-2R, IL-6, IL-8, and IL-10. The assays were performed according to their instructions, and measurements were made with a Luminex 200 system (Millipore Corporation, Bedford, Massachusetts USA).

Statistical analysis
Statistical analyses were conducted using the t test for parametric data and the Mann–Whitney U test for non-parametric data. One-way analysis of variance (ANOVA), followed by the Bonferroni test, was used when there were more than two groups. All statistical tests were two-sided, and the significance level was set at P<0.05. All analyses were conducted with SPSS 17.0 (SPSS, Inc). The data are shown as the mean ± standard error of the mean.

Results
Safety evaluation
No serious acute adverse events occurred during or after MSCT. Three patients had chills or fever (≤ 39 °C) after MSC infusion but recovered within 3 h without any intervention. No patients developed graft-versus-host disease (GVHD), and no serious infections occurred. No significant abnormalities were found according to routine blood tests, liver and kidney function analysis, chest radiography, urine analysis, or electrocardiography.

After 48 weeks, the response group (n = 28) showed significant increases in hemoglobin and albumin levels and decreases in platelet levels; these findings indicate immune function improvements (Table 1).

Assessment of disease activity
During the 12 weeks of follow-up after MSCT, 28 patients in the MSCT group had rapidly improved clinical symptoms with decreases in disease activity and drug dosage after MSCT. However, the other 24 patients in the MSCT group and the patients in the control group (n=53) did not show signs of improvement. According to the study protocol, we divided the patients in the MSCT group into a response group (n = 28) that had a good or moderate response and a no-response group (n = 24) (Fig. 1) according to the EULAR response criteria, which are based on the DAS28 [11]; no significant differences among the groups were detected at baseline (Additional file 1: Table S1). In agreement with the decrease in C-reactive protein (CRP) levels and the erythrocyte sedimentation rate (ESR), the HAQ and DAS28 values of the response group were significantly decreased 12 weeks after MSCT (Fig. 2). These findings indicated an improvement in the disease status. In addition, most of the patients in the response group maintained these therapeutic effects for 48 weeks without continuous administration. However, 2 (8%) experienced relapse, which was indicated by an increase in the ESR and CRP levels and joint swelling and pain at 24 weeks. What is more, the prednisone acetate doses were successfully reduced stepwise in 23 patients in the response group after MSCT (Fig. 2e) and their drug plans were not modified 6 months before enrollment. Most enrolled patients completed 48 weeks follow-up, but there are 2 of the no-response group and 5 of the control group lost to follow-up.
Table 1  Safety evaluation on patients between response and no-response group

| Measures (normal value range) | No-response | | | Response | | |
|-------------------------------|-------------|----|----|-----------|----|----|
|                               | Before treatment | After treatment | Before treatment | After treatment |
| Total protein (65–85 g/L)    | 73.24 ± 4.32  | 72.52 ± 3.46 | 72.63 ± 5.21 | 74.64 ± 3.68 |
| Albumin (40–55 g/L)         | 33.23 ± 5.31  | 32.57 ± 3.54 | 32.54 ± 4.63 | 40.63 ± 3.25* |
| Globulin (20–40 g/L)        | 30.62 ± 3.57  | 31.39 ± 4.36 | 31.58 ± 4.23 | 32.13 ± 3.86 |
| Cholesterol (3.1–5.72 mmol/L) | 4.03 ± 1.34  | 4.23 ± 1.53 | 4.15 ± 1.26 | 4.28 ± 1.93 |
| Triglyceride (0.30–1.7 mmol/L) | 1.46 ± 0.69  | 1.49 ± 0.83 | 1.51 ± 0.38 | 1.43 ± 0.58 |
| Creatinine (41–73 μmol/L)   | 46.53 ± 13.52 | 45.36 ± 12.38 | 43.36 ± 12.78 | 45.25 ± 14.21 |
| Urea (2.6–7.5 mmol/L)       | 4.23 ± 1.35  | 4.34 ± 1.28 | 4.12 ± 1.24 | 4.15 ± 1.87 |
| Fasting blood glucose (3.9–6.1 mmol/L) | 4.74 ± 0.83 | 4.84 ± 0.96 | 4.67 ± 0.73 | 4.75 ± 0.86 |
| White blood cell (3.5–9.5) × 10^9 | 5.65 ± 1.35 | 5.78 ± 1.26 | 5.84 ± 1.39 | 5.59 ± 1.47 |
| Hemoglobin (115–150 g/L)    | 102.35 ± 18.79 | 103.24 ± 19.21 | 101.15 ± 19.82 | 113.46 ± 16.62* |
| Platelet (94–268) × 10^9    | 253.23 ± 68.31 | 262.31 ± 72.78 | 263.12 ± 70.24 | 223.19 ± 65.87* |

No-response group: n = 22; Response group: n = 28

Value: mean ± SEM, t test, * P < 0.05

Fig. 2  Assessment of disease activity. DAS28 value, HAQ score, ESR and CRP level before and after MSCT for the groups. a DAS28 value; b HAQ score; c serum ESR; d serum CRP level; e changes in prednisone acetate dosage after MSCT in the response group; each dot represents one patient in the response group (n = 23). * P < 0.05, versus the response group before MSCT; & P < 0.05, versus the no-response and control groups according to one-way ANOVA. The error bars indicate the SEM. CRP C-reactive protein, ESR erythrocyte sedimentation rate
Serological autoantibody profile findings
To further investigate the therapeutic effects of MSCT, autoantibodies including anti-CCP and RF levels were detected before and after MSCT. Anti-CCP and RF levels were decreased after transplantation in the response group (Fig. 3a and b), however, these changes were not statistically significant.

Immune function
RA is a severe, progressive, systemic inflammatory disease of unknown etiology. RA development is closely related to immune system disorders, which are mostly categorized by unbalanced immune homeostasis. Further tests showed that the percentage of CD4+CD25+Foxp3+ Tregs was increased and that the percentage of CD4+IL-17A+ Th17 cells was decreased in the response group compared to those in the no-response and control group (Fig. 3c). These findings support that MSCs play important roles in regulating immune homeostasis. In particular, a low ratio of CD4+CD25+Foxp3+ Treg to CD4+IL-17A+ Th17 cells (Treg/Th17) indicates an unbalanced immune status and excessive inflammation microenvironment. This low ratio was observed in all patients before MSCT, but it was gradually reversed in the response group after MSCT (Fig. 3d).

Inflammatory microenvironment
Because of their unbalanced immune status, RA patients are often characterized by a pro-inflammatory microenvironment, including high levels of interleukin (IL)-6...
and tumor necrosis factor-alpha (TNF-α) (Fig. 4a, b) and low levels of IL-10 (Fig. 4c). After MSCT, patients in the response group showed improved immune balance, as manifested by decreased IL-6 and TNF-α levels (Fig. 4a, b) and increased in IL-10 levels (Fig. 4c). The IL-6 and TNF-α levels gradually decreased, whereas IL-10 levels increased significantly at 4 weeks and then gradually decreased to normal levels after MSCT in the response group. However, no significant changes in IL-1β, IL-2R and IL-8 levels were observed (Fig. 4d–f).

**IFN-γ predicts clinical response to MSCT in RA patients**

Allogeneic MSCT resulted in a clinical response rate of 54% (28/52) in our single clinical studies. Based on the aforementioned data, we sought to determine the reason why the same MSCs led to different outcomes for responders and non-responders enrolled from a single-center. It is well known that inflammation is an important target for treating autoimmune diseases, and the immunosuppressive properties of endogenous MSCs depend on the presence of IFN-γ in the microenvironment [12]. Besides, our in vitro study found that stimulated with IFN-γ could significantly increase the expression of indoleamine 2,3-dioxygenase (IDO), a key enzyme involved in the immunomodulatory ability of MSCs (Additional file 3: Figure S1). Therefore, we hypothesized that IFN-γ levels may play a key role in the different outcomes of the response group and no-response group after MSCT. As expected, high serum IFN-γ levels (>2 pg/mL) were generally observed before and 4 weeks after MSCT in the response group (Fig. 5a). This increase in IFN-γ levels was unrelated to infections since none of the patients had infectious complications. Importantly, IFN-γ levels remained low in the no-response group (Fig. 5a). The response group of patients was divided into Before and After subgroups according to whether a high serum IFN-γ level was observed before or after MSCT. Rapid therapeutic efficacy, according to the Treg/Th17 ratio, was found in the Before subgroup, and significant differences were observed 2–3 weeks after the IFN-γ increase (Fig. 5b). IL-6, TNF-α and IL-10 levels followed the same trend as the Treg/Th17 ratio, although some changes were not significant (Fig. 5c–e). Further studies revealed that the decrease in the DAS28 value (ΔDAS28) at the 12-week evaluation was closely related to the increase in IFN-γ levels (ΔIFN-γ) over the 12 weeks (Fig. 5f).

**Fig. 4** Inflammatory microenvironment measurements in RA patients before and after MSCT. **a** Serum interleukin 6 (IL-6) level; **b** serum tumor necrosis factor-alpha (TNF-α) level; **c** serum interleukin 10 (IL-10) level; **d** serum interleukin 1b (IL-1b) level; **e** serum interleukin 2 receptor (IL-2R) level; **f** serum interleukin 8 (IL-8) level. *P < 0.05, versus response group before MSCT; &P < 0.05, versus the no-response and control groups according to one-way ANOVA. The error bars indicate the SEM.
A decrease in the number of bone marrow MSCs can be found in RA-like autoimmune diseases, and this decrease grows more severe with disease progression [13]. Recent studies have shown that MSCs can ameliorate arthritis in RA patients and animal models and that the immunosuppressive effect of MSCs may be turned off or even switched to a stimulatory effect [14]. However, many aspects of the role of MSCs in treating RA remain unclear. Our present study has substantiated the clinical safety and efficacy of MSCT for treating RA patients. However, consistent with the study design, the clinical efficacy of MSCT varied greatly. Twelve weeks after MSCT, 54% of the patients in the MSCT group achieved a good or moderate response, whereas the other 46% of patients in the MSCT group had no clinical response.

The intravenous infusion of UCMSCs is a safe and effective practice that can improve immune function and serologic indices. In addition to a significant decrease in disease activity as assessed by the DAS28 value and HAQ score, MSC infusion reversed the inflammatory microenvironment and rebalanced the immune system. In the MSCT response group, evidence of the clinical benefits was obtained, and the clinical manifestation improvements were likely related to the increased Treg/Th17 ratio, which resulted in decreased levels of inflammatory cytokine expression, ESR and CRP. These results suggest that anti-inflammation along with improved immune-modulation and induced immune-tolerance are likely to be the major mechanisms of MSCT. However, the effects of MSCs in vivo are not permanent. In the present study, 8% of patients had disease relapse at 24 weeks after a prior good or moderate response. Disease activity indices, such as ESR and CRP levels, reverted slightly toward baseline levels, concomitant with relapsed joint swelling and pain. Because of the safety profile of MSC infusion in clinical applications, another MSC infusion after 6 months may be necessary for RA patients with partial relapse.

Considering there are no significant differences in age, gender and disease status between response and non-response groups, as mentioned in Additional

![Figure 5](image_url)

**Fig. 5** High endogenous IFN-γ levels were associated with a reduced DAS28 value in RA patients. **a** Peak IFN-γ level before and 4 weeks after MSCT for the response and no-response groups, **b** ratio of CD4+CD25+Foxp3+Tregs to CD4+IL-17A+Th17 cells levels for CD4+ T cells for the Before and After subgroups of the response group, **c** serum interleukin 6 (IL-6) levels for the Before and After subgroups of the response group, **d** serum tumor necrosis factor-alpha (TNF-α) levels for the Before and After subgroups of the response group, **e** serum interleukin 10 (IL-10) levels for the Before and After subgroups of the response group, **f** correlation between ∆DAS28 (DAS28 (12 weeks after MSCT) − DAS28 (before MSCT)) and ∆IFN-γ (IFN-γ peak before and 12 weeks after MSCT) for the response and no-response groups. *P < 0.05, versus the previous time. The error bars indicate the SEM. Before: subgroup of the response group with increased IFN-γ before MSCT (n = 12); After: subgroup of the response group with increased IFN-γ after MSCT (n = 16).
Further investigation of IFN-γ-primed MSCs in animal models of RA will be crucial for developing novel MSC-based therapies for RA patients who respond poorly to MSCT. The current patients are still being followed, and more patients are being recruited to further confirm the safety and efficacy of MSCT as a new treatment modality for RA.

Conclusions
In the present study, we demonstrate that (1) allogenic MSC transplantation is safe, as no serious adverse events were observed during or after MSC transplantation; (2) MSCT was effective in some RA patients, as suggested by the reductions in the DAS28 value, HAQ score, CRP level, and ESR; (3) MSCT improved the autoantibody profile of patients who responded to the therapy; (4) the potential mechanisms of MSCT are likely to be the anti-inflammatory or immunomodulatory effects of MSCs, as well as restored immune balance and tolerance; (5) serum IFN-γ levels may be a key factor that predicts the therapeutic effects of MSCs on RA patients.

Additional files

Additional file 1: Table S1. Clinical and demographic characteristics of the patients enrolled in the study.

Additional file 2. Source and preparation of MSCs.

Additional file 3: Figure S1. IFN-γ increases IDO expression of MSC in vitro.

Abbreviations
MSC: mesenchymal stem cell transplantation; RA: rheumatoid arthritis; DAS28: 28-joint Disease Activity Score; HAQ: Health Assessment Questionnaire; Treg: regulatory T cell; Th17: T helper 17; EULAR: European League Against Rheumatism; DMARDs: disease-modifying antirheumatic drugs; MSCs: mesenchymal stem cells; PBMCs: peripheral blood mononuclear cells; IFN-γ: interferon-γ; IDO: indoleamine 2,3-dioxygenase; GVHD: graft-versus-host disease; SLE: systemic lupus erythematosus; NSAIDs: non-steroidal anti-inflammatory drugs; UCMSCs: umbilical cord–derived human MSCs; anti-CCP: anti-cyclic citrullinated peptide antibody; RF: rheumatoid factor; ANOVA: one-way analysis of variance; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; IL-6: interleukin-6; TNF-α: tumor necrosis factor-alpha; TSG-6: tumor necrosis factor receptor alpha.

Authors’ contributions
CL and XX conceived the project and designed the experiments. YY, XH, RZ, WG, MZ and WX conducted the experiments. YY and XH wrote the manuscript. XX, CL, and DJ revised the manuscript. All authors read and approved the final manuscript.

Author details
1 First Department, State Key Laboratory of Trauma, Burn and Combined Injury, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, People’s Republic of China. 2 Department of Rheumatology and Clinical Immunology, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, People’s Republic of China. 3 Department of Critical Care Medicine, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, People’s Republic of China.
Acknowledgements
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study was approved by the Ethics Committee of Daping Hospital, Third Military Medical University of the Chinese People’s Liberation Army. Written informed consent was provided in accordance with the Declaration of Helsinki.

Funding
This work was supported by the National Natural Science Foundation of China (NSFC, Nos. 81571912 and 81372027) and the Natural Scientific Foundation of Chongqing (Nos. cstc2014jcyjys10002 and cstc2015shmszx120108).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 11 May 2018 Accepted: 6 June 2018
Published online: 15 June 2018

References
1. Klarenbeek NB, Guler-Yuksel M, van der Kooij SM, Han KH, Rondlay HK, Kerstens PI, Seys PE, Huizinga TW, Dijkmans BA, Allaart CF. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis. 2011;70:1039–46.
2. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.
3. Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymalstromal cells. Transplantation. 2009;87:S45–9.
4. Siegel G, Schafer R, Dazzi F. The immunosuppressive properties of mesenchymal stem cells. Transplantation. 2009;87:545–9.
5. Aggarwal S, Pittenger MF. Human mesenchymalstem cells modulate alloimmune cell responses. Blood. 2005;105:1815–22.
6. Ghannam S, Pene J, Moquet-Torcy G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol. 2010;185:302–12.
7. Le Blanc K, Rasmusson I, Sundberg B, Goetherstrom C, Hassan M, Uzunel M, Ringdén O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–41.
8. Rafiei M, Campeau PM, Aguilar-Mahecha A, Buchanan M, Williams P, Birman E, Yuan S, Young YK, Boivin MN, Forner K, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol. 2009;182:5994–6002.
9. Liang J, Li X, Zhang H, Wang D, Feng X, Wang H, Hua B, Liu B, Sun L. Allogeneic mesenchymal stem cells transplantation in patients with refractory RA. Clin Rheumatol. 2012;31:157–61.
10. Wang L, Wang L, Cong X, Liu G, Zhou J, Bai B, Li Y, Bai W, Li M, Ji H, et al. Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy. Stem Cells Dev. 2013;22:3192–202.
11. van Riel PL, Renskers L. The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(Suppl 101):A40–4.
12. Liu Y, Wang L, Kikui T, Akiyama K, Dong C, Xu Y, Yang R, Chen W, Wang S, Shi S. Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α. Nat Med. 2011;17:1594–601.
13. Scott DL, Smolen JS, Kalden JR, van de Putte LB, Larsen A, Kvien TK, Schattenkirchner M, Nash P, Oed C, Loew-Friedrich I. European Leflunomide Study G. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis. 2001;60:913–23.
14. Djouad F, Fritz V, Apparrayi F, Louis-Plence P, Bony C, Sany J, Jorgensen C, Noel D. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum. 2005;52:1595–603.
15. Krampera M. Mesenchymal stromal cell ‘licensing’: a multistep process. Leukemia. 2011;25:1408–14.
16. Shi Y, Su J, Roberts AI, Shou P, Rabson AB, Ren G. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol. 2012;33:136–43.
17. Sudres M, Norol F, Trenad A, Grecoire S, Charlotte F, Levacher B, Latallade JJ, Bourrin P, Holy X, Vernant JP, et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol. 2006;176:7761–7.
18. Polchert D, Sabinsky J, Douglas G, Kidd M, Moardut A, Reina E, Genrich K, Mehrotra S, Setty S, Smith B, Bartholomew A. IFN-γgamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008;38:1745–55.
19. Dander E, Lucchini G, Vinci P, Introna M, Masciocchi F, Perseghin P, Balduzzi A, Bonanomi S, Longoni D, Gaipa G, et al. Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring. Leukemia. 2012;26:1681–4.